Tumor News and Research

RSS

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4.

4 Jun 2011

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

4 Jun 2011

Additional data supporting utility of PAM50 gene signature for breast cancer to be presented at ASCO 2011

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that researchers will present additional evidence for the potential utility of profiling breast cancer based on the PAM50 gene signature at the 2011 American Society of Clinical Oncology annual meeting taking place in Chicago, Illinois from June 3-7.

4 Jun 2011

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group investigators.

4 Jun 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL from June 3 to June 7, 2011.

4 Jun 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

4 Jun 2011

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators.

4 Jun 2011

Nuvera announces results of blinded study on breast cancer assay for taxane chemotherapy response

Nuvera Biosciences, a molecular diagnostics company that develops gene-based diagnostic assays for personalized medicine in cancer, announced the results of a blinded validation study on its breast cancer assay for taxane chemotherapy response.

4 Jun 2011

Cancer vaccine shows improved response rate in patients

A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.

3 Jun 2011

Delayed treatment could prove effective in certain medical conditions

In today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery store or for an Internet connection — is rarely considered a good thing.

3 Jun 2011

Lung-sparing surgery, photodynamic therapy improve survival of mesothelioma patients

Pleural mesothelioma patients who undergo lung-sparing surgery in combination with photodynamic therapy (PDT) show superior overall survival than patient treated using the conventional therapy of extrapleural pneumonectomy (EPP) with PDT, indicates new research from the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania.

3 Jun 2011

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.

3 Jun 2011

Elevated CRP levels predict poor prognosis of breast cancer

Levels of C-reactive protein (CRP) are increased in response to acute inflammation, infection and tissue damage. There are also reports that CRP levels are elevated because of cancer.

3 Jun 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.

2 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Nuvilex, Inc. announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

2 Jun 2011

Investigators to examine how Ephb2 gene causes ependymoma in children

Armed with new grant support, investigators at Nationwide Children's Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma.

2 Jun 2011

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated.

2 Jun 2011

Tumor News and Research

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

Additional data supporting utility of PAM50 gene signature for breast cancer to be presented at ASCO 2011

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

Nuvera announces results of blinded study on breast cancer assay for taxane chemotherapy response

Cancer vaccine shows improved response rate in patients

Delayed treatment could prove effective in certain medical conditions

Lung-sparing surgery, photodynamic therapy improve survival of mesothelioma patients

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

Elevated CRP levels predict poor prognosis of breast cancer

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Investigators to examine how Ephb2 gene causes ependymoma in children

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News